<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2319">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261270</url>
  </required_header>
  <id_info>
    <org_study_id>ASC09F-CTP-TJ-01</org_study_id>
    <nct_id>NCT04261270</nct_id>
  </id_info>
  <brief_title>A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia</brief_title>
  <official_title>A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound
      tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of comprehensive adverse outcome</measure>
    <time_frame>14 days</time_frame>
    <description>The definition of comprehensive adverse outcome is as follows:
SPO2≤93% without oxygen inhalation;
PaO2/FiO2≤300mmHg;
RR≥30 bpm without oxygen inhalation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of clinical remission</measure>
    <time_frame>28 days</time_frame>
    <description>The definition of clinical remission:
Based on the symptoms of the disease (fever,cough,diarrhea,myalgia,dyspnea) has been relieved for 48 hours;
There is no evidence of disease progression(New dyspnea, SpO2 decreased≥3%,RR≥30 bpm without oxygen inhalation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no fever</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no cough</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no dyspnea</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no need for oxygen inhalation</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of undetectable viral RNA</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ICU admission</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>2019-nCoV Pneumonia</condition>
  <arm_group>
    <arm_group_label>ASC09F+Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ritonavir+Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC09F+Oseltamivir</intervention_name>
    <description>ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day</description>
    <arm_group_label>ASC09F+Oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir+Oseltamivir</intervention_name>
    <description>Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day</description>
    <arm_group_label>Ritonavir+Oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>75mg ,once a day</description>
    <arm_group_label>Oseltamivir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18~55 years old, unlimited gender.

          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV and accompanied with clinical
             manifestations.

          3. Patients with newly diagnosed respiratory discomfort who have been hospitalized (The
             proper diagnosis time is less than 7 days).

          4. Women who have no planned pregnancy in the next six months,and are willing to take
             effective measures to prevent contraception from the first dose of study drug to 30
             days after the last dose.

          5. Agree not to participate in other clinical studies within 30 days from the first dose
             of the study drug to the last dose.

          6. Patients who voluntarily sign informed consent forms.

        Exclusion Criteria:

        1.2019-nCoV severe Pneumonia patients.

        Meet the definition of severe pneumonia(Comply with any of the followings):

          1. Respiratory distress ,RR≥30 bpm;

          2. In a resting state:SPO2≤93%;

          3. PaO2/ FiO2≤300mmHg.

             2.2019-nCoV critical and severe Pneumonia patients.Comply with any of the
             followings:Respiratory failure and need mechanical ventilation;Shock;Patients combined
             with other organ failure need ICU monitoring and treatment.

             3.Severe liver disease(such as:the ChildPugh score≥C;AST &gt; 5 times the upper limit).

             4.Patients who are allergic to the ingredients of ASC09/ritonavir compound tablets.

             5.Patients with definite contraindications in ritonavir tablets.

             6.Female subjects were positive for the pregnancy test during the screening period.

             7.Researcher judges unsuitable for participation in this clinical trial(such as:during
             the study patients may be transferred to hospital for treatment;patients with multiple
             underlying diseases, etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qing Ning, Professor</last_name>
    <phone>+8613971521450</phone>
    <email>qning@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meifang Han, Professor</last_name>
    <phone>+8613986093605</phone>
    <email>mfhan@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department and Institute of Infectious Disease</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Ning, professor</last_name>
      <email>qning@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Meifang Han, professor</last_name>
      <email>mfhan@foxmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qin Ning</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

